Duplicate Reporting in Canada Just Got Addressed. Here’s What You Need to Know.

There’s a question that has frustrated Canadian MAHs for years: do we actually have to scan the Canada Vigilance database for cases to report?

On February 19, 2026, Health Canada answered it definitively. The answer is no, and the updated guidance goes further than many expected.

This isn’t a minor administrative tweak. It’s a signal that Health Canada is paying attention to where reporting burden accumulates and is willing to act on it. For anyone managing Canadian pharmacovigilance obligations, this is one of the more practically significant updates in recent years.

The Problem This Solves

Pharmacovigilance is built on a straightforward principle: the right information, reported by the right people, at the right time. When that system works well, regulators get the safety signal they need, patients are protected, and MAHs fulfil their obligations without wasting resources.

What it was never designed to do is generate the same case multiple times from multiple sources, creating noise in the system and unsustainable workloads for safety teams.

That’s exactly what had been happening. Health Canada acknowledged it directly in the notice: the previous guidance “has given rise to a significant increase in duplicate reporting and industry burden.” This update is the correction.

What the Guidance Actually Says

The notice, effective February 19, 2026, replaces section 4.3 of the 2018 guidance document and the 2020 Notice to Industry. If your SOPs reference either, they need updating immediately.

You are no longer required to scan the CV Online Database Adverse Reaction Online Database or the Health Product InfoWatch for ICSR reporting purposes. Full stop. Both obligations have been explicitly removed under section C.01.017 of the Food and Drug Regulations and section 24 of the Natural Health Products Regulations.

For foreign sources, including regulatory authority databases and scientific literature, you can now apply defined Exclusion Criteria for Product Identification. If you can determine using these criteria that a case does not relate to your product, you are not required to submit it. The full list of criteria is:

• Country of marketing
• Product name
• Active ingredient name
• Pharmaceutical form
• Batch number
• Marketing status
• Other characteristics

These criteria also override the previous language in sections 2.1.2 and 4.1.3 of the 2018 guidance, so they apply consistently across foreign regulatory authority sources and scientific literature alike.

One rule that has not changed and never will: if you cannot make a product identification determination using these criteria, you presume the product is yours, submit the ICSR, and indicate you couldn’t identify the specific brand. Uncertainty is not a basis for non-submission. The exclusion criteria give you a clear, defensible process, but only when you can actually apply them.

The Bigger Conversation This Opens

Regulators and industry have been circling a fundamental tension in pharmacovigilance for a long time: how do you maintain rigorous safety oversight without creating a compliance machine that consumes more resource than it generates value?

The honest answer is that duplicate reporting has never made patients safer. A case already in the Canada Vigilance database, submitted by another MAH, a consumer, or a healthcare professional, does not become more informative because your team re-submits it. What it does is consume case processing time, reviewer capacity, and database clarity that could be directed toward genuine safety signals.

Health Canada’s decision to formalise exclusion criteria reflects mature regulatory thinking. It distinguishes between the appearance of thoroughness, scanning every available database, and actual pharmacovigilance value. That distinction matters enormously, especially as safety teams are being asked to do more with the same or fewer resources.

We’re seeing the same logic play out globally. The EU’s Implementing Regulation 2025/1466, which came into full effect in February 2026, shifted signal validation responsibilities from MAHs to the EMA and national competent authorities for EudraVigilance database monitoring, again, recognising that duplicating regulatory authority work at the MAH level creates burden without safety benefit. Different jurisdiction, different mechanism, same underlying principle.

The direction of travel is clear: regulators want MAHs focused on the safety work only MAHs can do, monitoring their own products, detecting signals in their own data, and responding to new safety information. The rest is noise reduction.

What This Means for Your Team Right Now

Update your SOPs. Any procedure referencing routine CV Online Database or the Health Product InfoWatch scanning for ICSR submission purposes is now out of date. This guidance is effective immediately and applies to pharmaceuticals, biologics, radiopharmaceuticals, and natural health products.

Embed the exclusion criteria into your case intake process. These seven criteria should be applied consistently and documented at the point of foreign case receipt. They’re not a judgment call, they’re a defined framework. Use them as one.

Make your decisions auditable. When you decide not to submit based on exclusion criteria, that decision needs to be recorded. Inspectors will not simply accept that a case was excluded, they will want to see the criteria applied, documented, and consistent across your team.

Brief your case processing team. This is a workflow change, not just a policy update. The people handling day-to-day foreign case receipt need to understand what the criteria are, how to apply them, and what to do when they can’t.

Stay Ahead of What’s Coming Next

Changes like this one don’t arrive with much warning. One day the guidance says one thing, the next it says another, and the expectation is that your processes reflect the update immediately. For global MAHs, that challenge is multiplied across every market you operate in.

This is exactly the problem iVigee was built to solve. Our global network of local pharmacovigilance experts spans over 120 countries, giving you on-the-ground regulatory intelligence and local representation wherever your products are marketed. We don’t just monitor regulatory changes, we interpret them, translate them into practical action, and help you implement them before they become a compliance gap.

Whether you need support updating your Canadian PV procedures, a local expert to keep you ahead of Health Canada’s evolving expectations, or a partner who can provide that same coverage across every market simultaneously, we’re ready to help.

Get in touch with the iVigee team today. Tell us where you operate and what you’re managing, and we’ll show you exactly how we can keep you compliant, covered, and ahead of the curve, everywhere.

Source: Health Canada Notice: Clarification of Section 4.3, February 19, 2026